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ORIGINAL ARTICLE – HEPATOBILIARY TUMORS
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ABSTRACT
Background. Intraoperative blood cell salvage and autotransfusion (IBSA) during liver transplantation (LT) for
hepatocellular carcinoma (HCC) is controversial for concern regarding adversely impacting oncologic outcomes.
Objective. We aimed to evaluate the long-term oncologic
outcomes of patients who underwent LT with incidentally
discovered HCC who received IBSA compared with those
who did not receive IBSA.
Methods. Patients undergoing LT (January 2001–October
2018) with incidental HCC on explant pathology were
retrospectively identified. A 1:1 propensity score matching
(PSM) was performed. HCC recurrence and patient survival were compared. Kaplan–Meier survival analyses
were performed, and univariable Cox proportional hazard
analyses were performed for risks of recurrence and death.

Tommy Ivanics and Christopher R. Shubert have contributed equally.

Results. Overall, 110 patients were identified (IBSA,
n = 76 [69.1%]; non-IBSA, n = 34 [30.9%]). Before
matching, the groups were similar in terms of demographics, transplant, and tumor characteristics. Overall
survival was similar for IBSA and non-IBSA at 1, 3, and
5 years (96.0%, 88.4%, 83.0% vs. 97.1%, 91.1%, 87.8%,
respectively; p = 0.79). Similarly, the recurrence rate at 1,
3, and 5 years was not statistically different (IBSA 0%,
1.8%, 1.8% vs. non-IBSA 0%, 3.2%, 3.2%, respectively;
p = 0.55). After 1:1 matching (26 IBSA, 26 non-IBSA),
Cox proportional hazard analysis demonstrated similar risk
of death and recurrence between the groups (IBSA hazard
ratio [HR] of death 1.26, 95% confidence interval [CI]
0.52–3.05, p = 0.61; and HR of recurrence 2.64, 95% CI
0.28–25.30, p = 0.40).
Conclusions. IBSA does not appear to adversely impact
oncologic outcomes in patients undergoing LT with incidental HCC. This evidence further supports the need for
randomized trials evaluating the impact of IBSA use in LT
for HCC.
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Blood loss during liver transplantation (LT) often
necessitates transfusion. Intraoperative blood cell salvage
and autotransfusion (IBSA) is frequently deployed in LT to
avoid or decrease allogeneic transfusion use. Allogeneic
blood products have many drawbacks, including the
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association with increased morbidity and mortality,1,2
increased cost, infectious exposure, and antibody formation.3 IBSA mitigates many of these risks and has several
advantages over traditional allogeneic blood transfusions in
terms of avoidance of immunomodulation and antibody
formation, cost effectiveness, and also a decrease in a
recipient’s exposure to transfusion-related infections.3
LT offers curative-intent potential for patients with
hepatocellular carcinoma (HCC) who meet the strict
selection criteria, such as the Milan criteria.4 In addition,
LT also corrects any underlying cirrhosis. HCC is the
leading indication for LT at many centers.5,6 Despite the
near routine need for transfusion during LT, IBSA is rarely
used in LT for HCC due to the potential risk of disseminating cancer cells to the patient when blood loss is
salvaged and autotransfused. Therefore, HCC patients
undergoing LT at many centers receive allogeneic blood
products exclusively.
Several studies, primarily in Asia, have demonstrated no
adverse outcomes in overall survival or recurrence for
patients receiving IBSA during LT for HCC compared with
those who do not receive IBSA.7–11 Several studies in
urologic and gynecologic oncology surgery also have
shown no adverse oncologic outcomes with the use of
IBSA.12–14 Furthermore, IBSA use in hepatic surgery has
been evaluated and found to be safe, reduces the allogeneic
blood transfusion rate, and may even promote survival
compared with allogeneic transfusion.15,16 Currently, there
is a paucity of data from North American LT centers
regarding oncologic outcomes with IBSA use during LT
for HCC. Therefore, in many North American LT centers,
the use of IBSA during LT for HCC continues to be controversial for concerns of adversely impacting oncologic
outcomes.
Despite the lack of IBSA use in LT for HCC, incidental
HCC on explant pathology following LT is common,
especially in patients with viral hepatitis-related cirrhosis.
Therefore, in centers that utilize IBSA during LT, patients
with incidental HCC may receive IBSA inadvertently.
Therefore, we sought to evaluate the long-term oncologic
outcomes of patients who underwent LT with incidentally
discovered HCC on final explant pathology who received
IBSA, compared with a similar group of patients with
incidental HCC who did not receive IBSA, to assess the
overall oncologic risks.
METHODS
This study was approved by our institutional Research
Ethics Board (REB; REB#15-9989) and a waiver of
informed consent was obtained.

Study Population
We assessed adults (C18 years) who underwent LT
between January 2001 and October 2018 at our institution.
Patients were followed until March 2020. All patients were
listed and underwent LT for indications other than HCC
but had HCC diagnosed incidentally on the liver explant
specimen. At our institution, IBSA is available and used in
every non-cancer LT; however, not all patients from whom
blood is salvaged have blood autotransfused (e.g. volume
overload or low blood volume salvaged). Patients were
grouped into IBSA and non-IBSA groups depending on
whether they received salvage blood autotransfusion during
the LT.
We recorded patients’ age, sex, etiology of liver disease,
Model for End-Stage Liver Disease (MELD) score at LT,
Child–Pugh score at LT, serum a-fetoprotein (AFP) at LT,
time on the waitlist, amount and type of blood products
transfused (intra- and postoperatively [up to 48 h]), type of
allograft (deceased vs. living donor), preoperative hemoglobin (g/L), platelets (*1000) and international normalized
ratio (INR), intraoperative estimated blood loss (L), warm
ischemic time (WIT; minutes), cold ischemia time (CIT;
minutes), and previous abdominal surgery. AFP was categorized to reflect clinically relevant categories (ng/mL,
\20, 20–99, 100–999, [1000). Explant pathology characteristics included the number of tumors, size of the
largest tumor, microvascular invasion, and tumor differentiation. Tumor differentiation was defined according to
the modified Edmondson criteria.17 This study complies
with the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) statement for retrospective studies.18
Process of Intraoperative Blood Cell Salvage
and Autotransfusion and Institutional Policy
Blood salvage was performed using Cell Saver 5
(Haemonetics, Braintree, MA, USA). Shed blood from the
operative field was suctioned to the reservoir of the device
containing anticoagulant. If sufficient blood was collected,
it underwent centrifugation and washing and was processed
to a red blood cell (RBC) concentrate (approximately
50–80% hematocrit). Once the re-infusion bag reached
500 mL, the salvaged blood was autotransfused for a target
intraoperative blood hemoglobin of 80 g/L. No leukocyte
depletion filter was used in the process of cell salvage. Per
our institutional policy, IBSA is contraindicated in any
surgical procedure involving HCC.

Cell Salvage in Incidental HCC

Outcome Measures

RESULTS

The study’s primary endpoints were the impact of
intraoperative IBSA on post-LT survival and HCC tumor
recurrence.

Study Population and Pathology

Propensity Score Matching
A propensity score was constructed based on the predicted probability of IBSA receipt using logistic regression.
This was performed to control for the effect of confounding
and represents a method for addressing selection bias.
Covariates selected were variables that are associated with
degree of liver dysfunction and blood loss during LT.19–24
Given that the variables are associated with blood loss, by
extension we posited that they would also be associated
with IBSA receipt (blood cell salvage autotransfusion).
These included preoperative hemoglobin,20,22 MELD,19,20
preoperative platelet count,24 preoperative INR,24 Child–
Pugh score,21,25 allograft type, WIT,19 previous abdominal
surgery,21 CIT,25 and recipient age.19 Matching was then
performed using these covariates in a 1:1 ratio between
IBSA and non-IBSA receipt using a greedy, nearestneighbor matching algorithm with no replacement.26
Matching quality was evaluated with standardized mean
differences between the treated and control groups. A
difference \10% was used as indicative of a negligible
imbalance between groups.27
Statistical Analysis
Descriptive data were expressed using medians and
interquartile range (IQR) and compared using Student’s ttests and Mann–Whitney U tests. Categorical variables
were expressed using number percentages and compared
using Chi-square and Fisher’s exact tests. Disease-free
survival was defined as patients being alive without
recurrence at last follow-up. Disease-free and overall survival were estimated using the Kaplan–Meier method, and
groups were compared using log-rank tests. Univariable
Cox proportional hazard regression models were constructed after matching to evaluate the impact of IBSA on
mortality and recurrence. A multivariable model was not
performed as propensity score matching (PSM) was
selected as the method for confounding adjustment. All
two-sided p-values \0.05 were considered statistically
significant. Statistical analyses were performed using SAS
version 9.4 (SAS Institute Inc., Cary, NC, USA).

Between January 2001 and October 2018, 110 LT
patients with incidental HCC on explant pathology were
identified. Of these, 76 (69.1%) received IBSA and 34
(30.9%) did not. The median blood volume autotransfused
in the IBSA group was 750 mL (IQR 500–1480). The two
groups were similar in age, sex, etiology of liver disease,
serum AFP at LT, Child–Pugh score, and MELD score at
LT. The most common etiology of liver disease was hepatitis C virus (HCV) cirrhosis in both groups (IBSA 42.1%
vs. non-IBSA 52.9%; p = 0.86). The time on the LT
waitlist was similar between the groups (median number of
months [IQR] IBSA 4.7 [1.9–14.5] vs. non-IBSA 3.4
[1.4–9.3]; p = 0.35). The units of allogeneic pRBC and
platelets transfused were similar between groups. The
majority of patients received a deceased donor liver graft
(71.8%), and the proportions of deceased donor liver
transplant (DDLT) and living donor liver transplant
(LDLT) patients were similar between the IBSA and nonIBSA groups. The amount and types of blood products
used intra- and postoperatively were similar between the
groups (Table 1)
Explant Pathology
Both groups were similar in terms of tumor number
(median [IQR] IBSA 11,2 vs. non-IBSA 11,2; p = 0.50),
size of the largest tumor (median, cm [IQR] IBSA 1.2
[0.8–1.6] vs. non-IBSA 1.5 [1.0–1.8]; p = 0.11), rates of
microvascular invasion (IBSA 7.9% vs. non-IBSA 8.8%),
and tumor differentiation (moderate differentiation IBSA
69.3% vs. non-IBSA 83.3%; p = 0.40) (Table 1)
Survival Analysis in the Unmatched Cohort
The post-LT follow-up was similar between groups
(median months [IQR] IBSA 68.4 [36.3–92.9] vs. nonIBSA 70.8 [17.3–105.1]; p = 0.94). Overall survival was
similar at 1, 3, and 5 years (IBSA 96.0%, 88.4%, 83.0% vs.
non-IBSA 97.1%, 91.1%, 87.8%, respectively; p = 0.79).
Similarly, recurrence rate was not statistically different at
1, 3, and 5 years (IBSA 0%, 1.8%, 1.8% vs. non-IBSA 0%,
3.2%, 3.2%, respectively; p = 0.55) (Figs. 1 and 2). Of the
four patients who recurred, two had intrahepatic recurrence
(both in the IBSA group) and two had extrahepatic recurrence (both in the non-IBSA group).
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TABLE 1 Descriptive statistics in the IBSA and no IBSA transfusion groups before matching
Overall
(n = 110)

IBSA (n = 76
(69.1%))

No IBSA (n = 34
(30.9%))

pvaluea

SMD

Demographics and tumor characteristics
Age, years [median (IQR)]

55.5 (50.9–60.9)

56.0 (51.6–60.9)

54.6 (49.5–60.2)

0.63

0.016

Sex, male [n (%)]

91 (82.7)

61 (80.3)

30 (88.2)

0.31

0.23

Etiology of cirrhosis [n (%)]

0.86

Hepatitis C infection

50 (45.5)

32 (42.1)

18 (52.9)

0.28

Hepatitis B infection

11 (10.0)

8 (10.5)

3 (8.8)

0.06

NASH
Acute liver disease

18 (16.4)
22 (20.0)

14 (18.4)
16 (21.1)

4 (11.8)
6 (17.7)

0.16
0.11

Others

9 (8.2)

6 (7.9)

3 (8.8)

Serum AFP at transplant, ng/mL [n (%)]

0.08
0.85

0.002

\ 20

99 (90.8)

69 (92.0)

30 (88.2)

20–99

7 (6.4)

4 (5.3)

3 (8.8)

100–999

3 (2.8)

2 (2.7)

1 (3.0)

[ 1000

0 (0.0)

0 (0.0)

0 (0.0)

A

2 (1.8)

1 (1.3)

1 (3.0)

0.11

B

36 (32.7)

25 (32.9)

11 (32.4)

0.02

C

Child–Pugh score [n (%)]

0.84

72 (65.5)

50 (65.8)

22 (64.7)

MELD score at transplant [median (IQR)]

22 (18–26)

21 (17–25)

22.5 (20–27)

0.28

0.02
0.20

Previous abdominal surgery [n (%)]

27 (24.5)

21 (27.6)

6 (17.7)

0.26

0.22

99 (86–111)
68 (47–92)

99.5 (87–112)
70.5 (48–93.5)

95.5 (82–109)
67 (42–88)

0.24
0.73

0.19
0.06

INR pretransplant [median (IQR)]b

1.8 (1.5–2.3)

1.8 (1.5–2.3)

1.9 (1.6–2.5)

0.20

0.22

Estimated blood loss, ml [median (IQR)]b

2.6 (1.5–5)

3.2 (2–5.5)

2 (0–4)

0.002

0.57

Postoperative transfusion (up to 48 h post-transplant)
[n (%)]

68 (61.8)

49 (64.5)

19 (55.9)

0.39

0.26

RBC

36 (32.7)

23 (30.3)

13 (38.2)

0.41

0.14

FFP

23 (20.9)

14 (18.4)

9 (26.5)

0.34

0.27

Platelets

24 (21.8)

15 (19.7)

9 (26.5)

0.43

0.23

Cryoprecipitate

2 (1.8)

1 (1.3)

1 (2.9)

0.52

0.12

Albumin

52 (47.3)

39 (51.3)

13 (38.2)

0.20

0.32

0 (0–1)

0 (0–1)

0 (0–1.5)

0.23

0.61

Liver transplant characteristics
Hemoglobin pretransplant, g/L [median (IQR)]b
Platelets pretransplant, times 1000 [median (IQR)]

b

Number of postoperative RBC transfusions
Number of postoperative FFP transfusions

0 (0–0)

0 (0–0)

0 (0–1.5)

0.19

0.56

Number of postoperative platelet transfusions
Number of postoperative cryoprecipitate transfusions

0 (0–0)
0 (0–0)

0 (0–0)
0 (0–0)

0 (0–1.5)
0 (0–0)

0.33
0.53

0.31
0.26

Number of postoperative albumin transfusions

0 (0–2)

1 (0–2)

0 (0–2)

0.36

0.26

WIT, min [median (IQR)]b

50 (41.5–59.0)

47.5 (40.5–59)

53 (47–58)

0.34

0.25

CIT, min [median (IQR)]b

358 (166–502)

358 (184–502)

339 (158–520)

0.92

0.03

Operation duration, min [median (IQR)]b

488 (420–570)

483 (420–570)

493 (411–546)

0.70

0.02

Time on the waiting list, months [median (IQR)]

3.8 (1.7–13.9)

4.7 (1.9–14.5)

3.4 (1.4–9.3)

0.35

0.10

Units of intraoperative pRBC transfusions [median
(IQR)]

5 (3–8)

5 (3–7)

6 (4–10)

0.05

0.38

Units of intraoperative platelet transfusions [median
(IQR)]

2 (1–5)

2 (1–5)

2 (1–5)

0.83

0.17

Blood given through cell saver, mL [median (IQR)]

750 (500–1480)

750 (500–1480)

–

–

–

Cell Salvage in Incidental HCC
TABLE 1 contiuned
Overall
(n = 110)

IBSA (n = 76
(69.1%))

No IBSA (n = 34
(30.9%))

pvaluea

Type of graft [n (%)]

SMD

0.12

Deceased donor liver graft

79 (71.8)

58 (76.3)

21 (61.8)

0.26

Living donor liver graft

31 (28.2)

18 (23.7)

13 (38.2)

0.26

Explant pathology characteristics
Number of viable tumors at explant [median (IQR)]

1 (1–2)

1 (1–2)

1 (1–2)

0.77

0.16

Size of the largest viable tumor at explant, cm [median
(IQR)]

1.2 (1.0–1.7)

1.2 (0.8–1.6)

1.5 (1.0–1.8)

0.11

0.29

Microvascular invasion [n (%)]

9 (8.18)

6 (7.9)

3 (8.8)

1.0

0.03

Tumor differentiation [n (%)]

0.40

Well differentiated

25 (23.8)

20 (26.7)

5 (16.7)

0.46

Moderately differentiated

77 (73.3)

52 (69.3)

25 (83.3)

0.21

Poorly differentiated

3 (2.7)

3 (4.0)

0 (0)

–

Outcomes
Tumor recurrence [n (%)]

4 (3.6)

2 (5.9)

2 (2.6)

0.59

Time to recurrence, months [median (IQR)]

84.2 (27.1–141.2)

46.7 (31.2–62.2)

1.0

Death [n (%)]

46.7
(29.1–101.7)
30 (27.3)

18 (23.7)

12 (35.3)

0.25

Time to death, months [median (IQR)]

70.8 (36.3–92.9)

68.4 (36.3–92.9)

70.8 (17.3–105.1)

0.94

AFP a-fetoprotein, CIT cold ischemia time, FFP fresh frozen plasma, IBSA intraoperative blood salvage autotransfusion, INR international
normalized ratio, IQR interquartile range, MELD Model for End-stage Liver Disease, NASH non-alcoholic steatohepatitis, pRBC packed red
blood cells, RBC red blood cells, SMD standardized mean difference, WIT warm ischemia time
a
P value corresponds to a two-sided Student t-test comparison between patients who received cell saver transfusion and patients who did not
b

1.0

1.0

0.8

0.8

Probability

Probability

Missing \6

0.6

0.4

0.6

0.4
IBSA

IBSA

Log-rank p=0.55

0.2

1-year
3-year
5-year

IBSA
Not used

0.0
0

1

Number at risk
Not used 34
33
69
Used 76

2

Used
0%
1.8%
1.8%

Not used
0%
3.2%
3.2%

Used
3

4

5

29
51

26
47

25
44

FIG. 1 Recurrence based on IBSA use in the unmatched cohort.
IBSA intraoperative blood cell salvage and autotransfusion

1-year
3-year
5-year

IBSA
Not used

0.0

Years after transplant
32
57

Log-rank p=0.79

0.2

0

1

Number at risk
Not used 34
33
69
Used 76

2

Used
96.0%
88.4%
83.0%

Not used
97.1%
91.1%
87.8%

Used
3

4

5

26
46

25
44

Years after transplant
32
57

29
50

FIG. 2 Overall survival based on IBSA use in the unmatched cohort.
IBSA intraoperative blood cell salvage and autotransfusion
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Matched Cohort
Following PSM, 26 IBSA patients were matched with
26 non-IBSA patients. The standardized mean difference
was \10% between groups (Table 2). Univariable Cox
proportional hazard regression for risk of death demonstrated an equivalent risk between groups in the matched
cohort (IBSA [ref. non-IBSA] HR 1.26, 95% CI 0.52–3.05;
p = 0.61). The recurrence risk was also similar between
groups (IBSA [ref. non-IBSA] HR 2.64, 95% CI
0.28–25.30; p = 0.40).
DISCUSSION
These findings demonstrate that IBSA use does not
significantly impact oncologic outcomes of overall survival
or recurrence in patients undergoing LT with incidentally
discovered HCC. Moreover, the observed recurrence rates
in IBSA do not exceed what has been traditionally accepted
for post-LT HCC recurrence.
In the 1990s, Hansen et al. detected circulating tumor
cells in a majority (93.4%) of 61 cancer patients during
various oncologic surgeries. These cells demonstrated
proliferative capacity, invasiveness, and tumorigenicity. As
a consequence, caution was expressed towards autotransfusion of blood during oncologic surgery.28 The process of
IBSA was subsequently refined with leukocyte depletion
filters, which could remove tumor cells and reduce the risk
of tumor re-introduction during the cell-salvage process,
although the efficacy of leukocyte depletion filters remains
unproven by high-level prospective clinical data.29 Gwak
et al. evaluated the ability of one leukocyte depletion filter
to remove HCC tumor cells.29 Six groups of progressively
increasing amounts of tumor cells were passed through the
filter and subsequently evaluated using polymerase chain
reaction on the resuspended pellet that remained after the
filtration process.29 The authors noted that the filter could
remove tumor cells, although its effectiveness diminished
with increasing HCC cell counts.29 Nonetheless, several
subsequent retrospective studies, mostly from Asia, have
further demonstrated no increase in the risk of cancer
recurrence with a leukocyte depletion filter in the process
of IBSA use during LT for HCC, suggesting that either the
number of tumor cells that enter the filtration process are
few, the tumor cells that may re-enter the circulation do not
harbor the potential for seeding and metastasis development, or that the process of autotransfusion does not alter
the natural biological course of the disease.8–11,30 The
largest of these was by Han et al. from Korea, who performed a PSM analysis of LDLT recipients in whom the
indication for LT was HCC.7 Of 397 matched LDLT HCC
patients, there were 222 IBSA patients and 97 non-IBSA
patients.7 There were no differences in the cumulative

HCC recurrence rate at 1, 2, and 5 years (IBSA 10.8%,
14.9%, 20.3% vs. 10.4%, 19.1%, and 24.1%, respectively).7 Similarly, the groups were equivalent in risk for
overall, intrahepatic, or extrahepatic recurrence.7 In contrast to many of the previously reported studies, our series
did not use leukocyte depletion filters for any of the cases.
The studies that show equivalent oncologic outcomes
between the IBSA and non-IBSA groups offer further
evidence of oncologic safety of IBSA use during LT for
HCC and suggest the urgent need for a prospective trial.
From these studies, contraindication of IBSA during surgical procedures for HCC is unwarranted. The adverse
oncologic effects of IBSA are mostly theoretical, and many
of the abovementioned retrospective studies have failed to
corroborate this association. Nonetheless, due to the lowlevel evidence afforded by their study designs, the development of safe clinical guidelines has been precluded. A
clinical randomized control trial would address these limitations; however, it is further hindered by ethical
constraints that oncologic safety cannot be guaranteed,
again based on low-level evidence.
Moreover, likely reflective of the long study period and
high center LT volume, our study presents the largest
cohort of incidental HCCs after LT to date.31–33 In a previous report by Pérez et al., oncologic outcomes of 27
incidental HCC patients after LT were compared with 141
patients with known HCC.32 Both groups had similar rates
of multinodular disease, vascular invasion, and tumor differentiation.32 Although there was no difference between
the risk of tumor recurrence on adjusted analysis, incidental
HCC represented an independent risk for post-LT mortality. In that study, the 5-year recurrence-free survival was
79.7%, which was lower than the 5-year recurrence-free
survival rates reported in our study of 98.2% and 96.8% in
the IBSA and non-IBSA groups, respectively. Our results
are also comparable with reported post-LT recurrence in
the current literature, ranging from 9.8 to 17.3%.34,35 Our
study did not specifically aim to compare the outcomes of
incidental HCC after LT with patients known to have HCC
before LT; however, it does highlight that the oncologic
risk, despite overall favorable tumor characteristics, is not
negligible. As incidental HCCs carry a low risk of recurrence, conclusions cannot be directly extrapolated to
patients with known HCC at the time of LT, who have a
more significant tumor burden. Moreover, the presence and
role of circulating tumor cells in patients with early HCC
remains to be elucidated. Nonetheless, the results presented
herein offer evidence for oncologic safety of cell-saver use,
at least for the incidental HCCs, and further reinforce the
need for a randomized clinical trial for higher-level evidence to drive potential practice change.
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TABLE 2 Descriptive statistics in the IBSA and no IBSA transfusion groups after matching
IBSA [n = 26]

No IBSA [n = 26]

p-valuea

SMD

Demographics and tumor characteristics
Age, years [median (IQR)]

54.9 (52.6–61.6)

54.6 (50.0–59.5)

0.58

0.1

Sex, male [n (%)]

18 (69.2)

22 (84.6)

0.19

0.44

Hepatitis C infection

12 (46.2)

13 (50)

0.08

Hepatitis B infection

3 (11.5)

3 (11.5)

0.00

NASH

5 (15.4)

4 (15.4)

0.10

Acute liver disease

4 (15.4)

5 (19.2)

0.10

Others

2 (4.7)

1 (3.9)

0.14

\ 20
0–99

24 (92.3)
1 (3.8)

23 (88.5)
3 (11.5)

100–999

1 (3.8)

0 (0)

[ 1000

–

–

A

1 (3.85)

1 (3.85)

0.00

B

10 (38.5)

9 (34.6)

0.08

Etiology of cirrhosis [n (%)]

0.96

Serum AFP at transplant, ng/mL [n (%)]

0.36

Child–Pugh score [n (%)]

C

0.30

0.95

15 (57.7)

16 (61.5)

MELD score at transplant [median (IQR)]

21 (18–23)

22 (18–28)

0.32

0.10

0.08

Previous abdominal surgery [n (%)]

8 (30.8)

5 (19.2)

0.34

0.10

Liver transplant characteristics
Hemoglobin pretransplant, g/L [median (IQR)]b

101 (89–121)

99 (91–113)

0.28

0.11

Platelets pretransplant, times 1000 [median (IQR)]b

66.5 (52–98)

67.5 (46–88)

0.46

0.10

INR pretransplant [median (IQR)]b

1.8 (1.5–2.3)

1.8 (1.6–2.3)

0.64

0.02

Estimated blood loss, mL [median (IQR)]b

2 (1.5–3)

2 (0.8–4)

0.58

0.05

Postoperative transfusion [n (%)]

13 (50)

16 (61.5)

0.40

0.23

RBC
FFP

7 (26.9)
3 (11.5)

11 (42.3)
8 (30.8)

0.24
0.09

0.32
0.46

Platelets

5 (19.2)

9 (34.6)

0.21

0.37

Cryoprecipitate

0 (0)

1 (3.8)

0.31

0.26

Albumin

0.16

10 (38.5)

12 (46.2)

0.57

Number of postoperative RBC transfusions

0 (0–1)

0 (0–2)

0.12

0.34

Number of postoperative FFP transfusions

0 (0–0)

0 (0–2)

0.06

0.37

Number of postoperative platelet transfusions

0 (0–0)

0 (0–2)

0.24

0.29

Number of postoperative cryoprecipitate transfusions

0 (0–0)

0 (0–0)

0.32

0.11

Number of postoperative albumin transfusions

0 (0–2)

0 (0–2)

0.74

0.07

WIT, mins [median (IQR)]b

46 (40–56)

53 (47–57)

0.07

0.06

CIT, mins [median (IQR)]b

372 (120–497)

408 (191–540)

0.64

0.07

Operation duration, mins [median (IQR)]b

470 (410–570)

465 (400–510)

0.52

0.23

Time on the waiting list, months [median (IQR)]

4.9 (2.3–13.3)

3.8 (1.5–9.3)

0.53

0.14

Units of pRBC transfusion [median (IQR)]

3 (2–6)

6 (4–10)

0.007

0.41

Units of platelets transfusion [median (IQR)]
Blood given through cell saver, mL [median (IQR)]

1 (0–3)
550 (400–830)

2 (1–5)
–

0.19
–

0.01
–

Deceased donor liver graft

19 (73.1)

19 (73.1)

0.00

Living donor liver graft

7 (26.9)

7 (26.9)

0.00

1 (1–2)

1 (1–2)

Type of graft [n (%)]

1.0

Explant pathology characteristics
Number of viable tumors at explant [median (IQR)]

0.76

0.29
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TABLE 2 continued
IBSA [n = 26]

No IBSA [n = 26]

p-valuea

SMD

Size of the largest viable tumor at explant, cm
[median (IQR)]

1.15 (0.7–1.6)

1.5 (1.2–2.0)

0.03

0.37

Microvascular invasion [n (%)]

1 (3.8)

3 (11.5)

0.29

0.27

Tumor differentiation [n (%)]

0.10

Well differentiated

8 (30.8)

2 (9.1)

Moderately differentiated

17 (65.4)

20 (90.9)

0.62
0.26

Poorly differentiated

1 (3.8)

0 (0)

–

AFP a-fetoprotein, CIT cold ischemia time, FFP fresh frozen plasma, IBSA intraoperative blood salvage autotransfusion, INR international
normalized ratio, IQR interquartile range, MELD Model for End-stage Liver Disease, NASH non-alcoholic steatohepatitis, pRBC packed red
blood cells, RBC red blood cells, SMD standardized mean difference, WIT warm ischemia time
a

P-value corresponds to a two-sided Student t-test comparison between patients who received cell saver transfusion and patients who did not

b

Missing \6

Despite accumulating retrospective evidence, IBSA
remains contraindicated in many North American LT
centers (including our institution). Hence, the only possible
study population available to address our clinical question
was limited to LT patients with incidental HCCs on
explant. These patients predictably had favorable tumor
characteristics; they were generally small, solitary, and had
low rates of microvascular invasion. In our analysis, no
statistical difference in tumor characteristics was observed
between patients who received IBSA and those who did
not. Nonetheless, to the best of our knowledge, this is the
first report of IBSA use in North America.
Generally, IBSA is used during LT to reduce the
exposure to the recipient of allogeneic blood products,
which represent a scarce resource and carry the potential of
increasing morbidity and mortality.36,37 At University
Health Network, approximately 40–50% of LTs performed
every year are for patients with HCC. During LT for HCC,
significant blood loss is common and frequently requires
blood transfusion.23,38,39 At our institution, 72.9% of
patients receive an allogenic blood transfusion, either
intraoperatively or within the first 48 h after the LT for
HCC (unpublished data). This number can potentially be
reduced with the more widespread use of IBSA. Allogeneic
blood transfusions may lead to transfusion-associated
immunomodulation and, in some studies, are associated
with an increased risk of HCC recurrence following liver
resection; however, this remains controversial.1,2,40,41
IBSA affords advantages over traditional allogeneic blood
transfusions by not only potentially mitigating these factors
and limiting the immunomodulatory effect, which can be
detrimental, but possibly also by improving cost effectiveness.3 IBSA can also decrease a recipient’s exposure to
viruses, protozoa, and prions.3 Taken into combination,

increased use of IBSA for HCC, particularly in centers
where this indication represents the largest proportion of
patients undergoing LT, may decrease the amount of
allogeneic blood transfusions, and possibly morbidity and
mortality, without adversely impacting oncologic
outcomes.
Limitations
This study is limited by its retrospective and non-randomized design, with the potential for selection and
misclassification bias. Given the study’s single-institutional
nature, the results may not be generalizable to other centers. Despite this being the largest study in North America
to date, the number of patients is still small, limiting the
study’s statistical power to detect differences between
groups examined. Moreover, although adjustments have
been made for known covariates that may have confounded
the results, there is potential for residual confounding and
type 1 error.
CONCLUSION
IBSA does not appear to adversely impact oncologic
outcomes in patients undergoing LT with incidental HCC
compared with those not receiving IBSA. While the
recurrence risk in both the IBSA and non-IBSA groups is
not negligible, the rates are low and similar. This evidence
supports the further need for randomized trials evaluating
the impact of IBSA use in LT for HCC.
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